Call +1 (833) 552-7181 or Contact us Earn $25 in coupons on your first order with Aladdin!
Toggle Nav
My Cart
Search
Advanced Search
Menu
Sign In
྾
main product photo

Recombinant Aurora B Antibody - Primary antibody, specific to AURKB, Rabbit IgG

Features and benefits
  • Short Overview:

    Recombinant; Rabbit anti Human Aurora B Antibody; WB; Unconjugated

  • Species reactivity(Reacts with): Human
  • Isotype: Rabbit IgG
    Application:
  • WB
Item Number
Ab090289
Grouped product items
SKUSizeAvailabilityPrice Qty
Ab090289-10μl
10μl
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$66.90
Ab090289-50μl
50μl
In stock
$189.90
Ab090289-100μl
100μl
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$299.90
Ab090289-1ml
1ml
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$2,699.90
Add to Wish List Compare
Bulk Order  DATASHEET

Recombinant; Rabbit anti Human Aurora B Antibody; WB; Unconjugated

View related series
Click to view target information: AURKB
Accession#:Q96GD4 AURKB Aurora B Gene ID:9212

Basic Description

Product NameRecombinant Aurora B Antibody - Primary antibody, specific to AURKB, Rabbit IgG
SynonymsAIK2 antibody; AIM-1 antibody; AIM1 antibody; ARK-2 antibody; ARK2 antibody; AurB antibody; AURKB antibody; AURKB_HUMAN antibody; Aurora 1 antibody; Aurora and Ipl1 like midbody associated protein 1 antibody; Aurora kinase B antibody; Aurora related kinas
Specifications & PurityExactAb™, Validated, Recombinant, 0.3 mg/mL
Host speciesRabbit
SpecificityAURKB
ImmunogenA synthetic peptide derived from human Aurora B (AA 1-19)
Positive ControlWB: K562, HeLa, Jurkat, A549 and Hep G2 cell lysates.
ConjugationUnconjugated
GradeExactAb™, Recombinant, Validated
Product Description

Rabbit anti Human Aurora B Antibody, Recombinant, could be used for WB and so on.
Application:
WB: 1/500-1/1000
Protein Function
May be directly involved in regulating the cleavage of polar spindle microtubules and is a key regulator for the onset of cytokinesis during mitosis. Component of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis. The CPC complex has essential functions at the centromere in ensuring correct chromosome alignment and segregation and is required for chromatin-induced microtubule stabilization and spindle assembly. Phosphorylates 'Ser-10' and 'Ser-28' of histone H3 during mitosis. Required for kinetochore localization of BUB1 and SGOL1. Interacts with INCENP.

Product Properties

IsotypeRabbit IgG
SDS-PAGE150 kDa
Purification MethodAntigen affinity purified
FormLiquid
Concentration0.3 mg/mL
Storage TempStore at -20°C,Avoid repeated freezing and thawing
Shipped InIce chest + Ice pads
Stability And StorageStore at 4°C short term (1-2 weeks). Store at -20°C long term (24 months). Upon delivery aliquot. Avoid freeze/thaw cycle.

Images

Recombinant Aurora B Antibody (Ab090289) - Western Blot
All lanes: Recombinant Aurora B Antibody (Ab090289) at 1/1000 dilution
Samples: Lysates at 20 µg per lane
Secondary: Goat Anti-Rabbit IgG H&L (HRP) (Ab170144) at 1/20000 dilution

Predicted band size: 39 kDa
Observed band size: 39 kDa
Exposure time: 22.0 s


Associated Targets(Human)

AURKB Tchem Aurora kinase B (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
AURKB Tchem Serine/threonine-protein kinase Aurora-B (6805 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
AURKB Tchem Aurora kinase B/Inner centromere protein (233 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
AURKB Tchem Serine/threonine-protein kinase Aurora (2 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
AURKB Tchem Aurora kinase A/B (33 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Application

ApplicationDilution info
WB

1/500-1/1000

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

2 results found

Lot NumberCertificate TypeDateItem
ZJ23F1202188Certificate of AnalysisDec 28, 2023 Ab090289
ZJ23F1202187Certificate of AnalysisDec 28, 2023 Ab090289

Related Documents

 SDS

 Specification Sheet

FAQs and Articles

FAQ
Protocol and tips for whole mount immunohistochemical staining
Categories: Protocols
Tags:
Antibody Primary antibody Recombinant antibody IHC Immunohistochemical staining Whole mount immunohistochemical staining Epitope Tag Antibodies
Protocol of Western Blotting For High Molecular Weights
Categories: Protocols
Tags:
Western blotting Biological buffer Immunoblotting Protein Electrophoresis High Molecular Weights large molecular proteins WB antibody

References

1. Elkins JM, Santaguida S, Musacchio A, Knapp S.  (2012)  Crystal structure of human aurora B in complex with INCENP and VX-680..  J Med Chem,  55  (17): (7841-8).  [PMID:22920039]
2. Mollard A, Warner SL, Call LT, Wade ML, Bearss JJ, Verma A, Sharma S, Vankayalapati H, Bearss DJ.  (2011)  Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors..  ACS Med Chem Lett,  2  (12): (907-912).  [PMID:22247788]
3. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C et al..  (2007)  Patterns of somatic mutation in human cancer genomes..  Nature,  446  (7132): (153-8).  [PMID:17344846]
4. Hennequin LF, Allen J, Breed J, Curwen J, Fennell M, Green TP, Lambert-van der Brempt C, Morgentin R, Norman RA, Olivier A et al..  (2006)  N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor..  J Med Chem,  49  (22): (6465-88).  [PMID:17064066]
5. Szczepankiewicz BG, Kosogof C, Nelson LT, Liu G, Liu B, Zhao H, Serby MD, Xin Z, Liu M, Gum RJ et al..  (2006)  Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity..  J Med Chem,  49  (12): (3563-80).  [PMID:16759099]
6. Rowbottom MW, Faraoni R, Chao Q, Campbell BT, Lai AG, Setti E, Ezawa M, Sprankle KG, Abraham S, Tran L et al..  (2012)  Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E..  J Med Chem,  55  (3): (1082-105).  [PMID:22168626]
7. Estrada AA, Chan BK, Baker-Glenn C, Beresford A, Burdick DJ, Chambers M, Chen H, Dominguez SL, Dotson J, Drummond J et al..  (2014)  Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors..  J Med Chem,  57  (3): (921-36).  [PMID:24354345]
8. Fancelli D, Moll J, Varasi M, Bravo R, Artico R, Berta D, Bindi S, Cameron A, Candiani I, Cappella P et al..  (2006)  1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile..  J Med Chem,  49  (24): (7247-51).  [PMID:17125279]
9. Apsel B, Blair JA, Gonzalez B, Nazif TM, Feldman ME, Aizenstein B, Hoffman R, Williams RL, Shokat KM, Knight ZA.  (2008)  Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases..  Nat Chem Biol,  4  (11): (691-9).  [PMID:18849971]
10. Medina JR, Becker CJ, Blackledge CW, Duquenne C, Feng Y, Grant SW, Heerding D, Li WH, Miller WH, Romeril SP et al..  (2011)  Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors..  J Med Chem,  54  (6): (1871-95).  [PMID:21341675]
11. Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, Karaman MW, Pratz KW, Pallares G, Chao Q et al..  (2009)  AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)..  Blood,  114  (14): (2984-92).  [PMID:19654408]
12. Yang J, Ikezoe T, Nishioka C, Tasaka T, Taniguchi A, Kuwayama Y, Komatsu N, Bandobashi K, Togitani K, Koeffler HP et al..  (2007)  AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo..  Blood,  110  (6): (2034-40).  [PMID:17495131]
13. Payton M, Bush TL, Chung G, Ziegler B, Eden P, McElroy P, Ross S, Cee VJ, Deak HL, Hodous BL et al..  (2010)  Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines..  Cancer Res,  70  (23): (9846-54).  [PMID:20935223]
14. Shimomura T, Hasako S, Nakatsuru Y, Mita T, Ichikawa K, Kodera T, Sakai T, Nambu T, Miyamoto M, Takahashi I et al..  (2010)  MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel..  Mol Cancer Ther,  9  (1): (157-66).  [PMID:20053775]
15. Sampson PB, Liu Y, Patel NK, Feher M, Forrest B, Li SW, Edwards L, Laufer R, Lang Y, Ban F et al..  (2015)  The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents..  J Med Chem,  58  (1): (130-46).  [PMID:24867403]
16. Manfredi MG, Ecsedy JA, Meetze KA, Balani SK, Burenkova O, Chen W, Galvin KM, Hoar KM, Huck JJ, LeRoy PJ et al..  (2007)  Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase..  Proc Natl Acad Sci USA,  104  (10): (4106-11).  [PMID:17360485]
17. Shiotsu Y, Kiyoi H, Ishikawa Y, Tanizaki R, Shimizu M, Umehara H, Ishii K, Mori Y, Ozeki K, Minami Y et al..  (2009)  KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation..  Blood,  114  (8): (1607-17).  [PMID:19541823]
18. Goodfellow VS, Loweth CJ, Ravula SB, Wiemann T, Nguyen T, Xu Y, Todd DE, Sheppard D, Pollack S, Polesskaya O et al..  (2013)  Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3..  J Med Chem,  56  (20): (8032-48).  [PMID:24044867]
19. Weïwer M, Spoonamore J, Wei J, Guichard B, Ross NT, Masson K, Silkworth W, Dandapani S, Palmer M, Scherer CA et al..  (2012)  A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells..  ACS Med Chem Lett,  3  (12): (1034-1038).  [PMID:23256033]
20. Okuzumi T, Fiedler D, Zhang C, Gray DC, Aizenstein B, Hoffman R, Shokat KM.  (2009)  Inhibitor hijacking of Akt activation..  Nat Chem Biol,  5  (7): (484-93).  [PMID:19465931]
21. Weinberg LR, Albom MS, Angeles TS, Husten J, Lisko JG, McHugh RJ, Milkiewicz KL, Murthy S, Ott GR, Theroff JP et al..  (2011)  Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitors..  Bioorg Med Chem Lett,  21  (1): (164-7).  [PMID:21123062]
22. Milkiewicz KL, Aimone LD, Albom MS, Angeles TS, Chang H, Grobelny JV, Husten J, Losardo C, Miknyoczki S, Murthy S et al..  (2011)  Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group..  Bioorg Med Chem,  19  (21): (6274-84).  [PMID:21967808]
23. Adams ND, Adams JL, Burgess JL, Chaudhari AM, Copeland RA, Donatelli CA, Drewry DH, Fisher KE, Hamajima T, Hardwicke MA et al..  (2010)  Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase..  J Med Chem,  53  (10): (3973-4001).  [PMID:20420387]
24. Theodoulou NH, Bamborough P, Bannister AJ, Becher I, Bit RA, Che KH, Chung CW, Dittmann A, Drewes G, Drewry DH et al..  (2016)  Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition..  J Med Chem,  59  (4): (1425-39).  [PMID:25856009]
25. Papeo G, Posteri H, Borghi D, Busel AA, Caprera F, Casale E, Ciomei M, Cirla A, Corti E, D'Anello M et al..  (2015)  Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy..  J Med Chem,  58  (17): (6875-98).  [PMID:26222319]
26. Khan PM, Correa RG, Divlianska DB, Peddibhotla S, Sessions EH, Magnuson G, Brown B, Suyama E, Yuan H, Mangravita-Novo A et al..  (2011)  Identification of Inhibitors of NOD1-Induced Nuclear Factor-κB Activation..  ACS Med Chem Lett,  2  (10): (780-785).  [PMID:22003428]
27. Hobson AD, Harris CM, van der Kam EL, Turner SC, Abibi A, Aguirre AL, Bousquet P, Kebede T, Konopacki DB, Gintant G et al..  (2015)  Discovery of A-971432, An Orally Bioavailable Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonist for the Potential Treatment of Neurodegenerative Disorders..  J Med Chem,  58  (23): (9154-70).  [PMID:26509640]
28. Tan L, Gurbani D, Weisberg EL, Jones DS, Rao S, Singer WD, Bernard FM, Mowafy S, Jenney A, Du G et al..  (2017)  Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors..  Bioorg Med Chem,  25  (4): (1320-1328).  [PMID:28038940]
29. Glaser KB, Li J, Marcotte PA, Magoc TJ, Guo J, Reuter DR, Tapang P, Wei RQ, Pease LJ, Bui MH et al..  (2012)  Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families..  J Pharmacol Exp Ther,  343  (3): (617-27).  [PMID:22935731]
30. Heffron TP, Ndubaku CO, Salphati L, Alicke B, Cheong J, Drobnick J, Edgar K, Gould SE, Lee LB, Lesnick JD et al..  (2016)  Discovery of Clinical Development Candidate GDC-0084, a Brain Penetrant Inhibitor of PI3K and mTOR..  ACS Med Chem Lett,  7  (4): (351-6).  [PMID:27096040]
31. Barker MD, Liddle J, Atkinson FL, Wilson DM, Dickson MC, Ramirez-Molina C, Lewis H, Davis RP, Somers DO, Neu M et al..  (2018)  Discovery of potent and selective Spleen Tyrosine Kinase inhibitors for the topical treatment of inflammatory skin disease..  Bioorg Med Chem Lett,  28  (21): (3458-3462).  [PMID:30249354]
32. Castro-Falcón G, Seiler GS, Demir Ö, Rathinaswamy MK, Hamelin D, Hoffmann RM, Makowski SL, Letzel AC, Field SJ, Burke JE et al..  (2018)  Neolymphostin A Is a Covalent Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitor That Employs an Unusual Electrophilic Vinylogous Ester..  J Med Chem,  61  (23): (10463-10472).  [PMID:30380865]
33. Li Y, Xiong Y, Zhang G, Zhang L, Yang W, Yang J, Huang L, Qiao Z, Miao Z, Lin G et al..  (2018)  Identification of 5-(2,3-Dihydro-1 H-indol-5-yl)-7 H-pyrrolo[2,3- d]pyrimidin-4-amine Derivatives as a New Class of Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors, Which Showed Potent Activity in a Tumor Metastasis Model..  J Med Chem,  61  (24): (11398-11414).  [PMID:30480444]
34. Zhou Y, Shan S, Li ZB, Xin LJ, Pan DS, Yang QJ, Liu YP, Yue XP, Liu XR, Gao JZ et al..  (2017)  CS2164, a novel multi-target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potency..  Cancer Sci,  108  (3): (469-477).  [PMID:28004478]
35. Jarhad DB, Mashelkar KK, Kim HR, Noh M, Jeong LS.  (2018)  Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics..  J Med Chem,  61  (22): (9791-9810).  [PMID:29985601]
36. Czako B, Marszalek JR, Burke JP, Mandal P, Leonard PG, Cross JB, Mseeh F, Jiang Y, Chang EQ, Suzuki E et al..  (2020)  Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R..  J Med Chem,  129  (3): (589-97).  [PMID:32787110]
37. Yin L, Li H, Liu W, Yao Z, Cheng Z, Zhang H, Zou H.  (2018)  A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy..  Eur J Med Chem,  144  (3): (1-28).  [PMID:29247857]
38. Clark K, Plater L, Peggie M, Cohen P.  (2009)  Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation..  J Biol Chem,  284  (21): (14136-46).  [PMID:19307177]
39. Erki Enkvist, Darja Lavogina, Gerda Raidaru, Angela Vaasa, Indrek Viil, Marje Lust, Kaido Viht, Asko Uri,.  (2006-11-28)  Conjugation of adenosine and hexa-(D-arginine) leads to a nanomolar bisubstrate-analog inhibitor of basophilic protein kinases..  Journal of medicinal chemistry,  49  ((24)): ( 7150-7159 ).  [PMID:17125267]
40. Delphine Lamoral-Theys,Laurent Pottier,Frédéric Kerff,François Dufrasne,Fabien Proutière,Nathalie Wauthoz,Philippe Neven,Laurent Ingrassia,Pierre Van Antwerpen,Florence Lefranc,Michel Gelbcke,Bernard Pirotte,Jean-Louis Kraus,Jean Nève,Alexander Kornienko,Robert Kiss,Jacques Dubois.  (2010-05-15)  Simple di- and trivanillates exhibit cytostatic properties toward cancer cells resistant to pro-apoptotic stimuli..  Bioorganic & medicinal chemistry,  18  ((11)): (3823-3833).  [PMID:20466556]
41. Seunghee Hong,Jinhee Kim,Sun-Mi Yun,Hyunseung Lee,Yoonsu Park,Soon-Sun Hong,Sungwoo Hong.  (2013-04-23)  Discovery of new benzothiazole-based inhibitors of breakpoint cluster region-Abelson kinase including the T315I mutant..  Journal of medicinal chemistry,  56  ((9)): (3531-3545).  [PMID:23600806]
42. Ajit Dhananjay Jagtap,Pei-Teh Chang,Jia-Rong Liu,Hsiao-Chun Wang,Nagendra B Kondekar,Li-Jiuan Shen,Hsiang-Wen Tseng,Grace Shiahuy Chen,Ji-Wang Chern.  (2014-08-05)  Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia..  European journal of medicinal chemistry,  85  (268-288).  [PMID:25089810]
43. Emily J Hanan,Charles Eigenbrot,Marian C Bryan,Daniel J Burdick,Bryan K Chan,Yuan Chen,Jennafer Dotson,Robert A Heald,Philip S Jackson,Hank La,Michael D Lainchbury,Shiva Malek,Hans E Purkey,Gabriele Schaefer,Stephen Schmidt,Eileen M Seward,Steve Sideris,Christine Tam,Shumei Wang,Siew Kuen Yeap,Ivana Yen,Jianping Yin,Christine Yu,Inna Zilberleyb,Timothy P Heffron.  (2014-11-11)  Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutation..  Journal of medicinal chemistry,  57  ((23)): (10176-10191).  [PMID:25383627]
44. Xiao-Guang Bai,Dong-Ke Yu,Ju-Xian Wang,Hao Zhang,Hong-Wei He,Rong-Guang Shao,Xue-Mei Li,Yu-Cheng Wang.  (2012-10-06)  Design, synthesis and anticancer activity of 1-acyl-3-amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole derivatives..  Bioorganic & medicinal chemistry letters,  22  ((22)): (6947-6951).  [PMID:23036956]
45. Pevarello P, Brasca MG, Amici R, Orsini P, Traquandi G, Corti L, Piutti C, Sansonna P, Villa M, Pierce BS, Pulici M, Giordano P, Martina K, Fritzen EL, Nugent RA, Casale E, Cameron A, Ciomei M, Roletto F, Isacchi A, Fogliatto G, Pesenti E, Pastori W, Marsiglio A, Leach KL, Clare PM, Fiorentini F, Varasi M, Vulpetti A, Warpehoski MA..  (2004)  3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding..  J Med Chem,  47  (13): (3367-3380).  [PMID:15189033]
46. Zhao H, Serby MD, Xin Z, Szczepankiewicz BG, Liu M, Kosogof C, Liu B, Nelson LT, Johnson EF, Wang S, Pederson T, Gum RJ, Clampit JE, Haasch DL, Abad-Zapatero C, Fry EH, Rondinone C, Trevillyan JM, Sham HL, Liu G..  (2006)  Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-Jun NH2-terminal kinase inhibitors..  J Med Chem,  49  (15): (4455-4458).  [PMID:16854050]
47. DiMauro EF, Newcomb J, Nunes JJ, Bemis JE, Boucher C, Buchanan JL, Buckner WH, Cee VJ, Chai L, Deak HL, Epstein LF, Faust T, Gallant P, Geuns-Meyer SD, Gore A, Gu Y, Henkle B, Hodous BL, Hsieh F, Huang X, Kim JL, Lee JH, Martin MW, Masse CE, McGowan DC, Metz D, Mohn D, Morgenstern KA, Oliveira-dos-Santos A, Patel VF, Powers D, Rose PE, Schneider S, Tomlinson SA, Tudor YY, Turci SM, Welcher AA, White RD, Zhao H, Zhu L, Zhu X..  (2006)  Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity..  J Med Chem,  49  (19): (5671-5686).  [PMID:16970394]
48. Kishore AH, Vedamurthy BM, Mantelingu K, Agrawal S, Reddy BA, Roy S, Rangappa KS, Kundu TK..  (2008)  Specific small-molecule activator of Aurora kinase A induces autophosphorylation in a cell-free system..  J Med Chem,  51  (4): (792-797).  [PMID:18215015]
49. Weiss MM, Harmange JC, Polverino AJ, Bauer D, Berry L, Berry V, Borg G, Bready J, Chen D, Choquette D, Coxon A, DeMelfi T, Doerr N, Estrada J, Flynn J, Graceffa RF, Harriman SP, Kaufman S, La DS, Long A, Neervannan S, Patel VF, Potashman M, Regal K, Roveto PM, Schrag ML, Starnes C, Tasker A, Teffera Y, Whittington DA, Zanon R..  (2008)  Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors..  J Med Chem,  51  (6): (1668-1680).  [PMID:18324759]
50. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, Sordella R, Ulkus LE, Iafrate AJ, Maheswaran S, Njauw CN, Tsao H, Drew L, Hanke JH, Ma XJ, Erlander MG, Gray NS, Haber DA, Settleman J..  (2007)  Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling..  Proc Natl Acad Sci U S A,  104  (50): (19936-19941).  [PMID:18077425]
51. Feng Y, Yin Y, Weiser A, Griffin E, Cameron MD, Lin L, Ruiz C, Schürer SC, Inoue T, Rao PV, Schröter T, Lograsso P..  (2008)  Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors..  J Med Chem,  51  (21): (6642-6645).  [PMID:18834107]
52. Cha MY, Lee KO, Kim JW, Lee CG, Song JY, Kim YH, Lee GS, Park SB, Kim MS..  (2009)  Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer..  J Med Chem,  52  (21): (6880-6888).  [PMID:19888761]
53. Shomin CD, Meyer SC, Ghosh I..  (2009)  Staurosporine tethered peptide ligands that target cAMP-dependent protein kinase (PKA): optimization and selectivity profiling..  Bioorg Med Chem,  17  (17): (6196-6202).  [PMID:19674907]
54. Wee XK, Yeo WK, Zhang B, Tan VB, Lim KM, Tay TE, Go ML..  (2009)  Synthesis and evaluation of functionalized isoindigos as antiproliferative agents..  Bioorg Med Chem,  17  (21): (7562-7571).  [PMID:19783149]
55. Qiao L, Choi S, Case A, Gainer TG, Seyb K, Glicksman MA, Lo DC, Stein RL, Cuny GD..  (2009)  Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors..  Bioorg Med Chem Lett,  19  (21): (6122-6126).  [PMID:19783434]
56. Lesuisse D, Dutruc-Rosset G, Tiraboschi G, Dreyer MK, Maignan S, Chevalier A, Halley F, Bertrand P, Burgevin MC, Quarteronet D, Rooney T..  (2010)  Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2..  Bioorg Med Chem Lett,  20  (6): (1985-1989).  [PMID:20167481]
57. Bavetsias V, Large JM, Sun C, Bouloc N, Kosmopoulou M, Matteucci M, Wilsher NE, Martins V, Reynisson J, Atrash B, Faisal A, Urban F, Valenti M, de Haven Brandon A, Box G, Raynaud FI, Workman P, Eccles SA, Bayliss R, Blagg J, Linardopoulos S, McDonald E..  (2010)  Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate..  J Med Chem,  53  (14): (5213-5228).  [PMID:20565112]
58. Deng X, Lim SM, Zhang J, Gray NS..  (2010)  Broad spectrum alkynyl inhibitors of T315I Bcr-Abl..  Bioorg Med Chem Lett,  20  (14): (4196-4200).  [PMID:20541934]
59. Angiolini M, Banfi P, Casale E, Casuscelli F, Fiorelli C, Saccardo MB, Silvagni M, Zuccotto F..  (2010)  Structure-based optimization of potent PDK1 inhibitors..  Bioorg Med Chem Lett,  20  (14): (4095-4099).  [PMID:20621725]
60. Lesuisse D, Mauger J, Nemecek C, Maignan S, Boiziau J, Harlow G, Hittinger A, Ruf S, Strobel H, Nair A, Ritter K, Malleron JL, Dagallier A, El-Ahmad Y, Guilloteau JP, Guizani H, Bouchard H, Venot C..  (2011)  Discovery of the first non-ATP competitive IGF-1R kinase inhibitors: advantages in comparison with competitive inhibitors..  Bioorg Med Chem Lett,  21  (8): (2224-2228).  [PMID:21441024]
61. Ebada SS, Schulz B, Wray V, Totzke F, Kubbutat MH, Müller WE, Hamacher A, Kassack MU, Lin W, Proksch P..  (2011)  Arthrinins A-D: novel diterpenoids and further constituents from the sponge derived fungus Arthrinium sp..  Bioorg Med Chem,  19  (15): (4644-4651).  [PMID:21741249]
62. Ishikawa T, Seto M, Banno H, Kawakita Y, Oorui M, Taniguchi T, Ohta Y, Tamura T, Nakayama A, Miki H, Kamiguchi H, Tanaka T, Habuka N, Sogabe S, Yano J, Aertgeerts K, Kamiyama K..  (2011)  Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold..  J Med Chem,  54  (23): (8030-8050).  [PMID:22003817]
63. Caruso M, Valsasina B, Ballinari D, Bertrand J, Brasca MG, Caldarelli M, Cappella P, Fiorentini F, Gianellini LM, Scolaro A, Beria I..  (2012)  5-(2-amino-pyrimidin-4-yl)-1H-pyrrole and 2-(2-amino-pyrimidin-4-yl)-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one derivatives as new classes of selective and orally available Polo-like kinase 1 inhibitors..  Bioorg Med Chem Lett,  22  (1): (96-101).  [PMID:22154349]
64. Bijian K, Zhang Z, Xu B, Jie S, Chen B, Wan S, Wu J, Jiang T, Alaoui-Jamali MA..  (2012)  Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases..  Eur J Med Chem,  48  (143-152).  [PMID:22204902]
65. Cuny GD, Ulyanova NP, Patnaik D, Liu JF, Lin X, Auerbach K, Ray SS, Xian J, Glicksman MA, Stein RL, Higgins JM..  (2012)  Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors..  Bioorg Med Chem Lett,  22  (5): (2015-2019).  [PMID:22335895]
66. Zhang J, Deng X, Choi HG, Alessi DR, Gray NS..  (2012)  Characterization of TAE684 as a potent LRRK2 kinase inhibitor..  Bioorg Med Chem Lett,  22  (5): (1864-1869).  [PMID:22335897]
67. Jester BW, Gaj A, Shomin CD, Cox KJ, Ghosh I..  (2012)  Testing the promiscuity of commercial kinase inhibitors against the AGC kinase group using a split-luciferase screen..  J Med Chem,  55  (4): (1526-1537).  [PMID:22257127]
68. Leahy JW, Buhr CA, Johnson HW, Kim BG, Baik T, Cannoy J, Forsyth TP, Jeong JW, Lee MS, Ma S, Noson K, Wang L, Williams M, Nuss JM, Brooks E, Foster P, Goon L, Heald N, Holst C, Jaeger C, Lam S, Lougheed J, Nguyen L, Plonowski A, Song J, Stout T, Wu X, Yakes MF, Yu P, Zhang W, Lamb P, Raeber O..  (2012)  Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitors..  J Med Chem,  55  (11): (5467-5482).  [PMID:22548342]
69. Lawrence HR, Martin MP, Luo Y, Pireddu R, Yang H, Gevariya H, Ozcan S, Zhu JY, Kendig R, Rodriguez M, Elias R, Cheng JQ, Sebti SM, Schonbrunn E, Lawrence NJ..  (2012)  Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors..  J Med Chem,  55  (17): (7392-7416).  [PMID:22803810]
70. Sunose M, Bell K, Ellard K, Bergamini G, Neubauer G, Werner T, Ramsden N..  (2012)  Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease..  Bioorg Med Chem Lett,  22  (14): (4613-4618).  [PMID:22726925]
71. Reith AD, Bamborough P, Jandu K, Andreotti D, Mensah L, Dossang P, Choi HG, Deng X, Zhang J, Alessi DR, Gray NS..  (2012)  GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor..  Bioorg Med Chem Lett,  22  (17): (5625-5629).  [PMID:22863203]
72. Bavetsias V, Crumpler S, Sun C, Avery S, Atrash B, Faisal A, Moore AS, Kosmopoulou M, Brown N, Sheldrake PW, Bush K, Henley A, Box G, Valenti M, de Haven Brandon A, Raynaud FI, Workman P, Eccles SA, Bayliss R, Linardopoulos S, Blagg J..  (2012)  Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia..  J Med Chem,  55  (20): (8721-8734).  [PMID:23043539]
73. Yang LL, Li GB, Ma S, Zou C, Zhou S, Sun QZ, Cheng C, Chen X, Wang LJ, Feng S, Li LL, Yang SY..  (2013)  Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo..  J Med Chem,  56  (4): (1641-1655).  [PMID:23362959]
74. Dolečková I, Cesnek M, Dračinský M, Brynda J, Voller J, Janeba Z, Kryštof V..  (2013)  Synthesis and biological evaluation of guanidino analogues of roscovitine..  Eur J Med Chem,  62  (443-452).  [PMID:23399722]
75. Mortensen DS, Sapienza J, Lee BG, Perrin-Ninkovic SM, Harris R, Shevlin G, Parnes JS, Whitefield B, Hickman M, Khambatta G, Bisonette RR, Peng S, Gamez JC, Leisten J, Narla RK, Fultz KE, Sankar S..  (2013)  Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase..  Bioorg Med Chem Lett,  23  (6): (1588-1591).  [PMID:23414803]
76. Chapman TM, Osborne SA, Bouloc N, Large JM, Wallace C, Birchall K, Ansell KH, Jones HM, Taylor D, Clough B, Green JL, Holder AA..  (2013)  Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1)..  Bioorg Med Chem Lett,  23  (10): (3064-3069).  [PMID:23570789]
77. Kusakabe K, Ide N, Daigo Y, Tachibana Y, Itoh T, Yamamoto T, Hashizume H, Hato Y, Higashino K, Okano Y, Sato Y, Inoue M, Iguchi M, Kanazawa T, Ishioka Y, Dohi K, Kido Y, Sakamoto S, Yasuo K, Maeda M, Higaki M, Ueda K, Yoshizawa H, Baba Y, Shiota T, Murai H, Nakamura Y..  (2013)  Indazole-based potent and cell-active Mps1 kinase inhibitors: rational design from pan-kinase inhibitor anthrapyrazolone (SP600125)..  J Med Chem,  56  (11): (4343-4356).  [PMID:23634759]
78. Lin WH, Hsu JT, Hsieh SY, Chen CT, Song JS, Yen SC, Hsu T, Lu CT, Chen CH, Chou LH, Yang YN, Chiu CH, Chen CP, Tseng YJ, Yen KJ, Yeh CF, Chao YS, Yeh TK, Jiaang WT..  (2013)  Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3)..  Bioorg Med Chem,  21  (11): (2856-2867).  [PMID:23618709]
79. Shiao HY, Coumar MS, Chang CW, Ke YY, Chi YH, Chu CY, Sun HY, Chen CH, Lin WH, Fung KS, Kuo PC, Huang CT, Chang KY, Lu CT, Hsu JT, Chen CT, Jiaang WT, Chao YS, Hsieh HP..  (2013)  Optimization of ligand and lipophilic efficiency to identify an in vivo active furano-pyrimidine Aurora kinase inhibitor..  J Med Chem,  56  (13): (5247-5260).  [PMID:23808327]
80. Bowers S, Truong AP, Ye M, Aubele DL, Sealy JM, Neitz RJ, Hom RK, Chan W, Dappen MS, Galemmo RA, Konradi AW, Sham HL, Zhu YL, Beroza P, Tonn G, Zhang H, Hoffman J, Motter R, Fauss D, Tanaka P, Bova MP, Ren Z, Tam D, Ruslim L, Baker J, Pandya D, Diep L, Fitzgerald K, Artis DR, Anderson JP, Bergeron M..  (2013)  Design and synthesis of highly selective, orally active Polo-like kinase-2 (Plk-2) inhibitors..  Bioorg Med Chem Lett,  23  (9): (2743-2749).  [PMID:23522834]
81. Li J, Hu H, Lang Q, Zhang H, Huang Q, Wu Y, Yu L..  (2013)  A thienopyrimidine derivative induces growth inhibition and apoptosis in human cancer cell lines via inhibiting Aurora B kinase activity..  Eur J Med Chem,  65  (151-157).  [PMID:23707920]
82. Roy RV, Suman S, Das TP, Luevano JE, Damodaran C..  (2013)  Withaferin A, a steroidal lactone from Withania somnifera, induces mitotic catastrophe and growth arrest in prostate cancer cells..  J Nat Prod,  76  (10): (1909-1915).  [PMID:24079846]
83. Alder CM, Ambler M, Campbell AJ, Champigny AC, Deakin AM, Harling JD, Harris CA, Longstaff T, Lynn S, Maxwell AC, Mooney CJ, Scullion C, Singh OM, Smith IE, Somers DO, Tame CJ, Wayne G, Wilson C, Woolven JM..  (2013)  Identification of a Novel and Selective Series of Itk Inhibitors via a Template-Hopping Strategy..  ACS Med Chem Lett,  4  (10): (948-952).  [PMID:24900590]
84. Hu E, Kunz RK, Chen N, Rumfelt S, Siegmund A, Andrews K, Chmait S, Zhao S, Davis C, Chen H, Lester-Zeiner D, Ma J, Biorn C, Shi J, Porter A, Treanor J, Allen JR..  (2013)  Design, optimization, and biological evaluation of novel keto-benzimidazoles as potent and selective inhibitors of phosphodiesterase 10A (PDE10A)..  J Med Chem,  56  (21): (8781-8792).  [PMID:24102193]
85. Cheng X, Merz KH, Vatter S, Christ J, Wölfl S, Eisenbrand G..  (2014)  7,7'-Diazaindirubin--a small molecule inhibitor of casein kinase 2 in vitro and in cells..  Bioorg Med Chem,  22  (1): (247-255).  [PMID:24326279]
86. Naud S, Westwood IM, Faisal A, Sheldrake P, Bavetsias V, Atrash B, Cheung KM, Liu M, Hayes A, Schmitt J, Wood A, Choi V, Boxall K, Mak G, Gurden M, Valenti M, de Haven Brandon A, Henley A, Baker R, McAndrew C, Matijssen B, Burke R, Hoelder S, Eccles SA, Raynaud FI, Linardopoulos S, van Montfort RL, Blagg J..  (2013)  Structure-based design of orally bioavailable 1H-pyrrolo[3,2-c]pyridine inhibitors of mitotic kinase monopolar spindle 1 (MPS1)..  J Med Chem,  56  (24): (10045-10065).  [PMID:24256217]
87. Blake JF, Gaudino JJ, De Meese J, Mohr P, Chicarelli M, Tian H, Garrey R, Thomas A, Siedem CS, Welch MB, Kolakowski G, Kaus R, Burkard M, Martinson M, Chen H, Dean B, Dudley DA, Gould SE, Pacheco P, Shahidi-Latham S, Wang W, West K, Yin J, Moffat J, Schwarz JB..  (2014)  Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2..  Bioorg Med Chem Lett,  24  (12): (2635-2639).  [PMID:24813737]
88. Xie F, Zhu H, Zhang H, Lang Q, Tang L, Huang Q, Yu L..  (2015)  In vitro and in vivo characterization of a benzofuran derivative, a potential anticancer agent, as a novel Aurora B kinase inhibitor..  Eur J Med Chem,  89  (310-319).  [PMID:25462247]
89. Horbert R, Pinchuk B, Johannes E, Schlosser J, Schmidt D, Cappel D, Totzke F, Schächtele C, Peifer C..  (2015)  Optimization of potent DFG-in inhibitors of platelet derived growth factor receptorβ (PDGF-Rβ) guided by water thermodynamics..  J Med Chem,  58  (1): (170-182).  [PMID:25007344]
90. Carry JC, Clerc F, Minoux H, Schio L, Mauger J, Nair A, Parmantier E, Le Moigne R, Delorme C, Nicolas JP, Krick A, Abécassis PY, Crocq-Stuerga V, Pouzieux S, Delarbre L, Maignan S, Bertrand T, Bjergarde K, Ma N, Lachaud S, Guizani H, Lebel R, Doerflinger G, Monget S, Perron S, Gasse F, Angouillant-Boniface O, Filoche-Rommé B, Murer M, Gontier S, Prévost C, Monteiro ML, Combeau C..  (2015)  SAR156497, an exquisitely selective inhibitor of aurora kinases..  J Med Chem,  58  (1): (362-375).  [PMID:25369539]
91. Sampson PB, Liu Y, Forrest B, Cumming G, Li SW, Patel NK, Edwards L, Laufer R, Feher M, Ban F, Awrey DE, Mao G, Plotnikova O, Hodgson R, Beletskaya I, Mason JM, Luo X, Nadeem V, Wei X, Kiarash R, Madeira B, Huang P, Mak TW, Pan G, Pauls HW..  (2015)  The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent..  J Med Chem,  58  (1): (147-169).  [PMID:25723005]
92. Chen CT, Hsu JT, Lin WH, Lu CT, Yen SC, Hsu T, Huang YL, Song JS, Chen CH, Chou LH, Yen KJ, Chen CP, Kuo PC, Huang CL, Liu HE, Chao YS, Yeh TK, Jiaang WT..  (2015)  Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations..  Eur J Med Chem,  100  (151-161).  [PMID:26081023]
93. Yadav RR, Sharma S, Joshi P, Wani A, Vishwakarma RA, Kumar A, Bharate SB..  (2015)  Meridianin derivatives as potent Dyrk1A inhibitors and neuroprotective agents..  Bioorg Med Chem Lett,  25  (15): (2948-2952).  [PMID:26048785]
94. Lin XD, Yang HW, Ma S, Li WW, Zhang CH, Wang WJ, Xiang R, Li LL, Yang SY..  (2015)  Discovery of 6-phenylimidazo[2,1-b]thiazole derivatives as a new type of FLT3 inhibitors..  Bioorg Med Chem Lett,  25  (20): (4534-4538).  [PMID:26342867]
95. Charnley AK, Convery MA, Lakdawala Shah A, Jones E, Hardwicke P, Bridges A, Ouellette M, Totoritis R, Schwartz B, King BW, Wisnoski DD, Kang J, Eidam PM, Votta BJ, Gough PJ, Marquis RW, Bertin J, Casillas L..  (2015)  Crystal structures of human RIP2 kinase catalytic domain complexed with ATP-competitive inhibitors: Foundations for understanding inhibitor selectivity..  Bioorg Med Chem,  23  (21): (7000-7006).  [PMID:26455654]
96. Bavetsias V, Lanigan RM, Ruda GF, Atrash B, McLaughlin MG, Tumber A, Mok NY, Le Bihan YV, Dempster S, Boxall KJ, Jeganathan F, Hatch SB, Savitsky P, Velupillai S, Krojer T, England KS, Sejberg J, Thai C, Donovan A, Pal A, Scozzafava G, Bennett JM, Kawamura A, Johansson C, Szykowska A, Gileadi C, Burgess-Brown NA, von Delft F, Oppermann U, Walters Z, Shipley J, Raynaud FI, Westaway SM, Prinjha RK, Fedorov O, Burke R, Schofield CJ, Westwood IM, Bountra C, Müller S, van Montfort RL, Brennan PE, Blagg J..  (2016)  8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors..  J Med Chem,  59  (4): (1388-1409).  [PMID:26741168]
97. Schiemann K, Mallinger A, Wienke D, Esdar C, Poeschke O, Busch M, Rohdich F, Eccles SA, Schneider R, Raynaud FI, Czodrowski P, Musil D, Schwarz D, Urbahns K, Blagg J..  (2016)  Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore..  Bioorg Med Chem Lett,  26  (5): (1443-1451).  [PMID:26852363]
98. Song D, Lee M, Park CH, Ahn S, Yun CS, Lee CO, Kim HR, Hwang JY..  (2016)  Novel 2,4-diaminopyrimidines bearing tetrahydronaphthalenyl moiety against anaplastic lymphoma kinase (ALK): Synthesis, in vitro, ex vivo, and in vivo efficacy studies..  Bioorg Med Chem Lett,  26  (7): (1720-1725).  [PMID:26923695]
99. Greshock TJ, Sanders JM, Drolet RE, Rajapakse HA, Chang RK, Kim B, Rada VL, Tiscia HE, Su H, Lai MT, Sur SM, Sanchez RI, Bilodeau MT, Renger JJ, Kern JT, McCauley JA..  (2016)  Potent, selective and orally bioavailable leucine-rich repeat kinase 2 (LRRK2) inhibitors..  Bioorg Med Chem Lett,  26  (11): (2631-2635).  [PMID:27106707]
100. Daydé-Cazals B, Fauvel B, Singer M, Feneyrolles C, Bestgen B, Gassiot F, Spenlinhauer A, Warnault P, Van Hijfte N, Borjini N, Chevé G, Yasri A..  (2016)  Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors..  J Med Chem,  59  (8): (3886-3905).  [PMID:27010810]
101. Schroeder RL, Goyal N, Bratton M, Townley I, Pham NA, Tram P, Stone T, Geathers J, Nguyen K, Sridhar J..  (2016)  Identification of quinones as novel PIM1 kinase inhibitors..  Bioorg Med Chem Lett,  26  (13): (3187-3191).  [PMID:27173800]
102. An Y, Lee E, Yu Y, Yun J, Lee MY, Kang JS, Kim WY, Jeon R..  (2016)  Design and synthesis of novel benzoxazole analogs as Aurora B kinase inhibitors..  Bioorg Med Chem Lett,  26  (13): (3067-3072).  [PMID:27209235]
103. Laufer R, Li SW, Liu Y, Ng G, Lang Y, Feher M, Brokx R, Beletskaya I, Hodgson R, Mao G, Plotnikova O, Awrey DE, Mason JM, Wei X, Lin DC, Che Y, Kiarash R, Madeira B, Fletcher GC, Mak TW, Bray MR, Pauls HW..  (2016)  Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK..  Bioorg Med Chem Lett,  26  (15): (3562-3566).  [PMID:27335255]
104. Kumar V, Guru SK, Jain SK, Joshi P, Gandhi SG, Bharate SB, Bhushan S, Bharate SS, Vishwakarma RA..  (2016)  A chromatography-free isolation of rohitukine from leaves of Dysoxylum binectariferum: Evaluation for in vitro cytotoxicity, Cdk inhibition and physicochemical properties..  Bioorg Med Chem Lett,  26  (15): (3457-3463).  [PMID:27363938]
105. Kim H, Lee C, Yang JS, Choi S, Park CH, Kang JS, Oh SJ, Yun J, Kim MH, Han G..  (2016)  Structural modifications at the 6-position of thieno[2,3-d]pyrimidines and their effects on potency at FLT3 for treatment of acute myeloid leukemia..  Eur J Med Chem,  120  (74-85).  [PMID:27187860]
106. Klaeger S, Heinzlmeir S and Wilhelm M et al.  (2017)  The target landscape of clinical kinase drugs..  Science,  358  (6367):   [PMID:29191878]
107. Chen Y, Zheng Y, Jiang Q, Qin F, Zhang Y, Fu L, He G..  (2017)  Integrated bioinformatics, computational and experimental methods to discover novel Raf/extracellular-signal regulated kinase (ERK) dual inhibitors against breast cancer cells..  Eur J Med Chem,  127  (997-1011).  [PMID:27839788]
108. Argyros O, Lougiakis N, Kouvari E, Papafotika A, Raptopoulou CP, Psycharis V, Christoforidis S, Pouli N, Marakos P, Tamvakopoulos C..  (2017)  Design and synthesis of novel 7-aminosubstituted pyrido[2,3-b]pyrazines exhibiting anti-breast cancer activity..  Eur J Med Chem,  126  (954-968).  [PMID:28006668]
109. Shi Y, Park J, Lagisetti C, Zhou W, Sambucetti LC, Webb TR..  (2017)  A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore..  Bioorg Med Chem Lett,  27  (3): (406-412).  [PMID:28049589]
110. Hoemann M, Wilson N, Argiriadi M, Banach D, Burchat A, Calderwood D, Clapham B, Cox P, Duignan DB, Konopacki D, Somal G, Vasudevan A..  (2016)  Synthesis and optimization of furano[3,2-d]pyrimidines as selective spleen tyrosine kinase (Syk) inhibitors..  Bioorg Med Chem Lett,  26  (22): (5562-5567).  [PMID:27789138]
111. Li Y, Luo X, Guo Q, Nie Y, Wang T, Zhang C, Huang Z, Wang X, Liu Y, Chen Y, Zheng J, Yang S, Fan Y, Xiang R..  (2018)  Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo[2,3- d]pyrimidin-2-yl)amino)phenyl)- N8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer..  J Med Chem,  61  (7): (3166-3192).  [PMID:29518312]
112. Fukuda T, Goto R, Kiho T, Ueda K, Muramatsu S, Hashimoto M, Aki A, Watanabe K, Tanaka N..  (2017)  Discovery of DS79182026: A potent orally active hepcidin production inhibitor..  Bioorg Med Chem Lett,  27  (16): (3716-3722).  [PMID:28705644]
113. Patel S, Meilandt WJ, Erickson RI, Chen J, Deshmukh G, Estrada AA, Fuji RN, Gibbons P, Gustafson A, Harris SF, Imperio J, Liu W, Liu X, Liu Y, Lyssikatos JP, Ma C, Yin J, Lewcock JW, Siu M..  (2017)  Selective Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12) with Activity in a Model of Alzheimer's Disease..  J Med Chem,  60  (19): (8083-8102).  [PMID:28929759]
114. Fukuda T, Goto R, Kiho T, Ueda K, Muramatsu S, Hashimoto M, Aki A, Watanabe K, Tanaka N..  (2017)  Discovery of DS28120313 as a potent orally active hepcidin production inhibitor: Design and optimization of novel 4,6-disubstituted indazole derivatives..  Bioorg Med Chem Lett,  27  (23): (5252-5257).  [PMID:29079471]
115. Gege C, Cummings MD, Albers M, Kinzel O, Kleymann G, Schlüter T, Steeneck C, Nelen MI, Milligan C, Spurlino J, Xue X, Leonard K, Edwards JP, Fourie A, Goldberg SD, Hoffmann T..  (2018)  Identification and biological evaluation of thiazole-based inverse agonists of RORγt..  Bioorg Med Chem Lett,  28  (9): (1446-1455).  [PMID:29631962]
116. Diab S, Abdelaziz AM, Li P, Teo T, Basnet SKC, Noll B, Rahaman MH, Lu J, Hou J, Yu M, Le BT, Albrecht H, Milne RW, Wang S..  (2017)  Dual Inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia..  Eur J Med Chem,  139  (762-772).  [PMID:28863357]
117. Malínková V, Řezníčková E, Jorda R, Gucký T, Kryštof V..  (2017)  Trisubstituted purine inhibitors of PDGFRα and their antileukemic activity in the human eosinophilic cell line EOL-1..  Bioorg Med Chem,  25  (24): (6523-6535).  [PMID:29089259]
118. Monastyrskyi A, Nilchan N, Quereda V, Noguchi Y, Ruiz C, Grant W, Cameron M, Duckett D, Roush W..  (2018)  Development of dual casein kinase 1δ/1ε (CK1δ/ε) inhibitors for treatment of breast cancer..  Bioorg Med Chem,  26  (3): (590-602).  [PMID:29289448]
119. Myers SH, Temps C, Houston DR, Brunton VG, Unciti-Broceta A..  (2018)  Development of Potent Inhibitors of Receptor Tyrosine Kinases by Ligand-Based Drug Design and Target-Biased Phenotypic Screening..  J Med Chem,  61  (5): (2104-2110).  [PMID:29466002]
120. Assadieskandar A, Yu C, Maisonneuve P, Liu X, Chen YC, Prakash GKS, Kurinov I, Sicheri F, Zhang C..  (2018)  Effects of rigidity on the selectivity of protein kinase inhibitors..  Eur J Med Chem,  146  (519-528).  [PMID:29407977]
121. Wang Q, Liu F, Qi S, Qi Z, Yan XE, Wang B, Wang A, Wang W, Chen C, Liu X, Jiang Z, Hu Z, Wang L, Wang W, Ren T, Zhang S, Yun CH, Liu Q, Liu J..  (2018)  Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia..  Eur J Med Chem,  150  (366-384).  [PMID:29544149]
122. He LJ, Yang DL, Li SQ, Zhang YJ, Tang Y, Lei J, Frett B, Lin HK, Li HY, Chen ZZ, Xu ZG..  (2018)  Facile construction of fused benzimidazole-isoquinolinones that induce cell-cycle arrest and apoptosis in colorectal cancer cells..  Bioorg Med Chem,  26  (14): (3899-3908).  [PMID:29921474]
123. Thomas MG, De Rycker M, Cotillo Torrejon I, Thomas J, Riley J, Spinks D, Read KD, Miles TJ, Gilbert IH, Wyatt PG..  (2018)  2,4-Diamino-6-methylpyrimidines for the potential treatment of Chagas' disease..  Bioorg Med Chem Lett,  28  (18): (3025-3030).  [PMID:30104093]
124. Pan Z, Chen Y, Liu J, Jiang Q, Yang S, Guo L, He G..  (2018)  Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy..  Eur J Med Chem,  144  (517-528).  [PMID:29288948]
125. Fearon D, Westwood IM, van Montfort RLM, Bayliss R, Jones K, Bavetsias V..  (2018)  Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition..  Bioorg Med Chem,  26  (11): (3021-3029).  [PMID:29764757]
126. Jiang JK, Huang X, Shamim K, Patel PR, Lee A, Wang AQ, Nguyen K, Tawa G, Cuny GD, Yu PB, Zheng W, Xu X, Sanderson P, Huang W..  (2018)  Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors..  Bioorg Med Chem Lett,  28  (20): (3356-3362).  [PMID:30227946]
127. Wang B, Wu J, Wu Y, Chen C, Zou F, Wang A, Wu H, Hu Z, Jiang Z, Liu Q, Wang W, Zhang Y, Liu F, Zhao M, Hu J, Huang T, Ge J, Wang L, Ren T, Wang Y, Liu J, Liu Q..  (2018)  Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor..  Eur J Med Chem,  158  (896-916).  [PMID:30253346]
128. Long L, Wang YH, Zhuo JX, Tu ZC, Wu R, Yan M, Liu Q, Lu G..  (2018)  Structure-based drug design: Synthesis and biological evaluation of quinazolin-4-amine derivatives as selective Aurora A kinase inhibitors..  Eur J Med Chem,  157  (1361-1375).  [PMID:30196060]
129. Dodo K, Kuboki E, Shimizu T, Imamura R, Magarisawa M, Takahashi M, Tokuhiro T, Yotsumoto S, Asano K, Nakao S, Terayama N, Suda T, Tanaka M, Sodeoka M..  (2019)  Development of a Water-Soluble Indolylmaleimide Derivative IM-93 Showing Dual Inhibition of Ferroptosis and NETosis..  ACS Med Chem Lett,  10  (9): (1272-1278).  [PMID:31531196]
130. Zhang Q, Hu X, Wan G, Wang J, Li L, Wu X, Liu Z, Yu L..  (2019)  Discovery of 3-(((9H-purin-6-yl)amino)methyl)-4,6-dimethylpyridin-2(1H)-one derivatives as novel tubulin polymerization inhibitors for treatment of cancer..  Eur J Med Chem,  184  (111728-111728).  [PMID:31610375]
131. Rana S, Sonawane YA, Taylor MA, Kizhake S, Zahid M, Natarajan A..  (2018)  Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy..  Bioorg Med Chem Lett,  28  (23-24): (3736-3740).  [PMID:30343954]
132. Narayan S, Ramisetti S, Jaiswal AS, Law BK, Singh-Pillay A, Singh P, Amin S, Sharma AK..  (2019)  ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells..  Eur J Med Chem,  161  (456-467).  [PMID:30384048]
133. Osborne J, Birchall K, Tsagris DJ, Lewis SJ, Smiljanic-Hurley E, Taylor DL, Levy A, Alessi DR, McIver EG..  (2019)  Discovery of potent and selective 5-azaindazole inhibitors of leucine-rich repeat kinase 2 (LRRK2) - Part 1..  Bioorg Med Chem Lett,  29  (4): (668-673).  [PMID:30554956]
134. Wang Y, Dou X, Jiang L, Jin H, Zhang L, Zhang L, Liu Z..  (2019)  Discovery of novel glycogen synthase kinase-3α inhibitors: Structure-based virtual screening, preliminary SAR and biological evaluation for treatment of acute myeloid leukemia..  Eur J Med Chem,  171  (221-234).  [PMID:30925338]
135. Tang G, Liu L, Wang X, Pan Z..  (2019)  Discovery of 7H-pyrrolo[2,3-d]pyrimidine derivatives as selective covalent irreversible inhibitors of interleukin-2-inducible T-cell kinase (Itk)..  Eur J Med Chem,  173  (167-183).  [PMID:30999237]
136. Abdelaziz AM, Basnet SKC, Islam S, Li M, Tadesse S, Albrecht H, Gerber C, Yu M, Wang S..  (2019)  Synthesis and evaluation of 2'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'-dione derivatives as Mnk inhibitors..  Bioorg Med Chem Lett,  29  (18): (2650-2654).  [PMID:31362920]
137. Harris PA, Faucher N, George N, Eidam PM, King BW, White GV, Anderson NA, Bandyopadhyay D, Beal AM, Beneton V, Berger SB, Campobasso N, Campos S, Capriotti CA, Cox JA, Daugan A, Donche F, Fouchet MH, Finger JN, Geddes B, Gough PJ, Grondin P, Hoffman BL, Hoffman SJ, Hutchinson SE, Jeong JU, Jigorel E, Lamoureux P, Leister LK, Lich JD, Mahajan MK, Meslamani J, Mosley JE, Nagilla R, Nassau PM, Ng SL, Ouellette MT, Pasikanti KK, Potvain F, Reilly MA, Rivera EJ, Sautet S, Schaeffer MC, Sehon CA, Sun H, Thorpe JH, Totoritis RD, Ward P, Wellaway N, Wisnoski DD, Woolven JM, Bertin J, Marquis RW..  (2019)  Discovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) Kinase..  J Med Chem,  62  (10): (5096-5110).  [PMID:31013427]
138. Szabadkai I, Torka R, Garamvölgyi R, Baska F, Gyulavári P, Boros S, Illyés E, Choidas A, Ullrich A, Őrfi L..  (2018)  Discovery of N-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors..  J Med Chem,  61  (14): (6277-6292).  [PMID:29928803]
139. Qi B, Zhong L, He J, Zhang H, Li F, Wang T, Zou J, Lin YX, Zhang C, Guo X, Li R, Shi J..  (2019)  Discovery of Inhibitors of Aurora/PLK Targets as Anticancer Agents..  J Med Chem,  62  (17): (7697-7707).  [PMID:31381325]
140. Wang X, Yu C, Wang C, Ma Y, Wang T, Li Y, Huang Z, Zhou M, Sun P, Zheng J, Yang S, Fan Y, Xiang R..  (2019)  Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer..  Eur J Med Chem,  181  (111535-111535).  [PMID:31376566]
141. Zhao L, Li Y, Wang Y, Qiao Z, Miao Z, Yang J, Huang L, Tian C, Li L, Chen D, Yang S..  (2019)  Discovery of 4H-Chromen-4-one Derivatives as a New Class of Selective Rho Kinase (ROCK) Inhibitors, which Showed Potent Activity in ex Vivo Diabetic Retinopathy Models..  J Med Chem,  62  (23): (10691-10710).  [PMID:31693351]
142. Jang J, Son JB, To C, Bahcall M, Kim SY, Kang SY, Mushajiang M, Lee Y, Jänne PA, Choi HG, Gray NS..  (2017)  Discovery of a potent dual ALK and EGFR T790M inhibitor..  Eur J Med Chem,  136  (497-510).  [PMID:28528303]
143. Bronner SM, Merrick KA, Murray J, Salphati L, Moffat JG, Pang J, Sneeringer CJ, Dompe N, Cyr P, Purkey H, Boenig GL, Li J, Kolesnikov A, Larouche-Gauthier R, Lai KW, Shen X, Aubert-Nicol S, Chen YC, Cheong J, Crawford JJ, Hafner M, Haghshenas P, Jakalian A, Leclerc JP, Lim NK, O'Brien T, Plise EG, Shalan H, Sturino C, Wai J, Xiao Y, Yin J, Zhao L, Gould S, Olivero A, Heffron TP..  (2019)  Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma..  Bioorg Med Chem Lett,  29  (16): (2294-2301).  [PMID:31307887]
144. Oukoloff K, Coquelle N, Bartolini M, Naldi M, Le Guevel R, Bach S, Josselin B, Ruchaud S, Catto M, Pisani L, Denora N, Iacobazzi RM, Silman I, Sussman JL, Buron F, Colletier JP, Jean L, Routier S, Renard PY..  (2019)  Design, biological evaluation and X-ray crystallography of nanomolar multifunctional ligands targeting simultaneously acetylcholinesterase and glycogen synthase kinase-3..  Eur J Med Chem,  168  (58-77).  [PMID:30798053]
145. Asquith CRM, Naegeli KM, East MP, Laitinen T, Havener TM, Wells CI, Johnson GL, Drewry DH, Zuercher WJ, Morris DC..  (2019)  Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma..  J Med Chem,  62  (9): (4772-4778).  [PMID:30973735]
146. Shin SY, Ahn S, Yoon H, Jung H, Jung Y, Koh D, Lee YH, Lim Y..  (2016)  Colorectal anticancer activities of polymethoxylated 3-naphthyl-5-phenylpyrazoline-carbothioamides..  Bioorg Med Chem Lett,  26  (17): (4301-4309).  [PMID:27476140]
147. Allegretti PA, Horton TM, Abdolazimi Y, Moeller HP, Yeh B, Caffet M, Michel G, Smith M, Annes JP..  (2020)  Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization..  Bioorg Med Chem,  28  (1): (115193-115193).  [PMID:31757680]
148. Zak M,Hanan EJ,Lupardus P,Brown DG,Robinson C,Siu M,Lyssikatos JP,Romero FA,Zhao G,Kellar T,Mendonca R,Ray NC,Goodacre SC,Crackett PH,McLean N,Hurley CA,Yuen PW,Cheng YX,Liu X,Liimatta M,Kohli PB,Nonomiya J,Salmon G,Buckley G,Lloyd J,Gibbons P,Ghilardi N,Kenny JR,Johnson A.  (2019)  Discovery of a class of highly potent Janus Kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling..  Bioorg Med Chem Lett,  29  (12.0): (1522-1531).  [PMID:30981576]
149. Hamilton GL,Chen H,Deshmukh G,Eigenbrot C,Fong R,Johnson A,Kohli PB,Lupardus PJ,Liederer BM,Ramaswamy S,Wang H,Wang J,Xu Z,Zhu Y,Vucic D,Patel S.  (2019)  Potent and selective inhibitors of receptor-interacting protein kinase 1 that lack an aromatic back pocket group..  Bioorg Med Chem Lett,  29  (12.0): (1497-1501).  [PMID:31000154]
150. May-Dracka TL,Arduini R,Bertolotti-Ciarlet A,Bhisetti G,Brickelmaier M,Cahir-McFarland E,Enyedy I,Fontenot JD,Hesson T,Little K,Lyssikatos J,Marcotte D,McKee T,Murugan P,Patterson T,Peng H,Rushe M,Silvian L,Spilker K,Wu P,Xin Z,Burkly LC.  (2018)  Investigating small molecules to inhibit germinal center kinase-like kinase (GLK/MAP4K3) upstream of PKCθ phosphorylation: Potential therapy to modulate T cell dependent immunity..  Bioorg Med Chem Lett,  28  (10): (1964-1971).  [PMID:29636220]
151. Runfola M,Sestito S,Bellusci L,La Pietra V,D'Amore VM,Kowalik MA,Chiellini G,Gul S,Perra A,Columbano A,Marinelli L,Novellino E,Rapposelli S.  (2020)  Design, synthesis and biological evaluation of novel TRβ selective agonists sustained by ADME-toxicity analysis..  Eur J Med Chem,  188  (112006-112006).  [PMID:31931337]
152. Ding X,Stasi LP,Ho MH,Zhao B,Wang H,Long K,Xu Q,Sang Y,Sun C,Hu H,Yu H,Wan Z,Wang L,Edge C,Liu Q,Li Y,Dong K,Guan X,Tattersall FD,Reith AD,Ren F.  (2018)  Discovery of 4-ethoxy-7H-pyrrolo[2,3-d]pyrimidin-2-amines as potent, selective and orally bioavailable LRRK2 inhibitors..  Bioorg Med Chem Lett,  28  (9.0): (1615-1620).  [PMID:29588215]
153. Rojas-Prats E,Martinez-Gonzalez L,Gonzalo-Consuegra C,Liachko NF,Perez C,Ramírez D,Kraemer BC,Martin-Requero Á,Perez DI,Gil C,de Lago E,Martinez A.  (2021)  Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis..  Eur J Med Chem,  210  (112968-112968).  [PMID:33139113]
154. Yang J,Chen K,Zhang G,Yang QY,Li YS,Huang SZ,Wang YL,Yang W,Jiang XJ,Yan HX,Zhu JQ,Xiang R,Luo YF,Li WM,Wei YQ,Li LL,Yang SY.  (2018)  Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants..  Eur J Med Chem,  143  (1148-1164).  [PMID:29133048]
155. Fan C,Zhong T,Yang H,Yang Y,Wang D,Yang X,Xu Y,Fan Y.  (2020)  Design, synthesis, biological evaluation of 6-(2-amino-1H-benzo[d]imidazole-6-yl)quinazolin-4(3H)-one derivatives as novel anticancer agents with Aurora kinase inhibition..  Eur J Med Chem,  190  (112108-112108).  [PMID:32058239]
156. Lakkaniga NR,Zhang L,Belachew B,Gunaganti N,Frett B,Li HY.  (2020)  Discovery of SP-96, the first non-ATP-competitive Aurora Kinase B inhibitor, for reduced myelosuppression..  Eur J Med Chem,  203  (112589-112589).  [PMID:32717530]
157. Lakkaniga NR,Gunaganti N,Zhang L,Belachew B,Frett B,Leung YK,Li HY.  (2020)  Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation..  Eur J Med Chem,  206  (112691-112691).  [PMID:32823007]
158. Yan W, Zhang L, Lv F, Moccia M, Carlomagno F, Landry C, Santoro M, Gosselet F, Frett B, Li HY..  (2021)  Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation..  Eur J Med Chem,  216  (113265-113265).  [PMID:33652352]
159. Shindo, M M and 9 more authors..  (1998)  cDNA cloning, expression, subcellular localization, and chromosomal assignment of mammalian aurora homologues, aurora-related kinase (ARK) 1 and 2..  Biochemical and biophysical research communications,    (6):   [PMID:9514916]
160. Tatsuka, M M and 6 more authors..  (1998)  Multinuclearity and increased ploidy caused by overexpression of the aurora- and Ipl1-like midbody-associated protein mitotic kinase in human cancer cells..  Cancer research,    (1):   [PMID:9809983]
161. Kimura, M M, Matsuda, Y Y, Yoshioka, T T, Sumi, N N and Okano, Y Y..  (1998)  Identification and characterization of STK12/Aik2: a human gene related to aurora of Drosophila and yeast IPL1..  Cytogenetics and cell genetics,      [PMID:9858806]
162. and Nigg, E A EA..  (2001)  Mitotic kinases as regulators of cell division and its checkpoints..  Nature reviews. Molecular cell biology,      [PMID:11413462]
163. Prigent, C C, Gill, R R, Trower, M M and Sanseau, P P..  (1999)  In silico cloning of a new protein kinase, Aik2, related to Drosophila Aurora using the new tool: EST Blast..  In silico biology,      [PMID:11471245]
164. Wheatley, S P SP, Carvalho, A A, Vagnarelli, P P and Earnshaw, W C WC..  (2001)  INCENP is required for proper targeting of Survivin to the centromeres and the anaphase spindle during mitosis..  Current biology : CB,    (5):   [PMID:11516652]
165. Zeitlin, S G SG, Shelby, R D RD and Sullivan, K F KF..  (2001)  CENP-A is phosphorylated by Aurora B kinase and plays an unexpected role in completion of cytokinesis..  The Journal of cell biology,    (24):   [PMID:11756469]
166. Crosio, Claudia C and 8 more authors..  (2002)  Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases..  Molecular and cellular biology,      [PMID:11784863]
167. Goto, Hidemasa H, Yasui, Yoshihiro Y, Nigg, Erich A EA and Inagaki, Masaki M..  (2002)  Aurora-B phosphorylates Histone H3 at serine28 with regard to the mitotic chromosome condensation..  Genes to cells : devoted to molecular & cellular mechanisms,      [PMID:11856369]
168. Kawajiri, Aie A and 6 more authors..  (2003)  Functional significance of the specific sites phosphorylated in desmin at cleavage furrow: Aurora-B may phosphorylate and regulate type III intermediate filaments during cytokinesis coordinatedly with Rho-kinase..  Molecular biology of the cell,      [PMID:12686604]
169. Minoshima, Yukinori Y and 15 more authors..  (2003)  Phosphorylation by aurora B converts MgcRacGAP to a RhoGAP during cytokinesis..  Developmental cell,      [PMID:12689593]
170. Honda, Reiko R, Körner, Roman R and Nigg, Erich A EA..  (2003)  Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis..  Molecular biology of the cell,      [PMID:12925766]
171. Tien, An-Chi AC and 8 more authors..  (2004)  Identification of the substrates and interaction proteins of aurora kinases from a protein-protein interaction model..  Molecular & cellular proteomics : MCP,      [PMID:14602875]
172. Wheatley, Sally P SP, Henzing, Alexander J AJ, Dodson, Helen H, Khaled, Walid W and Earnshaw, William C WC..  (2004)  Aurora-B phosphorylation in vitro identifies a residue of survivin that is essential for its localization and binding to inner centromere protein (INCENP) in vivo..  The Journal of biological chemistry,    (13):   [PMID:14610074]
173. Shu, Fengjue F and 9 more authors..  (2003)  Human aurora-B binds to a proteasome alpha-subunit HC8 and undergoes degradation in a proteasome-dependent manner..  Molecular and cellular biochemistry,      [PMID:14674694]
174. Yasui, Yoshihiro Y and 9 more authors..  (2004)  Autophosphorylation of a newly identified site of Aurora-B is indispensable for cytokinesis..  The Journal of biological chemistry,    (26):   [PMID:14722118]
175. Johnson, Victoria L VL, Scott, Maria I F MI, Holt, Sarah V SV, Hussein, Deema D and Taylor, Stephen S SS..  (2004)  Bub1 is required for kinetochore localization of BubR1, Cenp-E, Cenp-F and Mad2, and chromosome congression..  Journal of cell science,    (15):   [PMID:15020684]
176. Delaval, Bénédicte B and 6 more authors..  (2004)  Aurora B -TACC1 protein complex in cytokinesis..  Oncogene,    (3):   [PMID:15064709]
177. Gassmann, Reto R and 8 more authors..  (2004)  Borealin: a novel chromosomal passenger required for stability of the bipolar mitotic spindle..  The Journal of cell biology,    (19):   [PMID:15249581]
178. Yüce, Ozlem O, Piekny, Alisa A and Glotzer, Michael M..  (2005)  An ECT2-centralspindlin complex regulates the localization and function of RhoA..  The Journal of cell biology,    (15):   [PMID:16103226]
179. Qi, Meiyan M and 11 more authors..  (2005)  Septin1, a new interaction partner for human serine/threonine kinase aurora-B..  Biochemical and biophysical research communications,    (28):   [PMID:16179162]
180. Zody, Michael C MC and 73 more authors..  (2006)  DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage..  Nature,    (20):   [PMID:16625196]
181. Tchatchou, Sandrine S and 10 more authors..  (2007)  Aurora kinases A and B and familial breast cancer risk..  Cancer letters,    (18):   [PMID:16762494]
182. Faitar, Silviu L SL, Sossey-Alaoui, Khalid K, Ranalli, Tamara A TA and Cowell, John K JK..  (2006)  EVI5 protein associates with the INCENP-aurora B kinase-survivin chromosomal passenger complex and is involved in the completion of cytokinesis..  Experimental cell research,    (15):   [PMID:16764853]
183. Sumara, Izabela I and 6 more authors..  (2007)  A Cul3-based E3 ligase removes Aurora B from mitotic chromosomes, regulating mitotic progression and completion of cytokinesis in human cells..  Developmental cell,      [PMID:17543862]
184. Pouwels, Jeroen J and 6 more authors..  (2007)  Shugoshin 1 plays a central role in kinetochore assembly and is required for kinetochore targeting of Plk1..  Cell cycle (Georgetown, Tex.),    (1):   [PMID:17617734]
185. North, Brian J BJ and Verdin, Eric E..  (2007)  Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during mitosis..  PloS one,    (29):   [PMID:17726514]
186. Xia, Fang F, Canovas, Pedro M PM, Guadagno, Thomas M TM and Altieri, Dario C DC..  (2008)  A survivin-ran complex regulates spindle formation in tumor cells..  Molecular and cellular biology,      [PMID:18591255]
187. Dephoure, Noah N and 6 more authors..  (2008)  A quantitative atlas of mitotic phosphorylation..  Proceedings of the National Academy of Sciences of the United States of America,    (5):   [PMID:18669648]
188. Daub, Henrik H and 9 more authors..  (2008)  Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle..  Molecular cell,    (8):   [PMID:18691976]
189. Yasen, Mahmut M and 11 more authors..  (2009)  Expression of Aurora B and alternative variant forms in hepatocellular carcinoma and adjacent tissue..  Cancer science,      [PMID:19134008]
190. Sardon, Teresa T, Cottin, Thomas T, Xu, Jing J, Giannis, Athanassios A and Vernos, Isabelle I..  (2009)  Development and biological evaluation of a novel aurora A kinase inhibitor..  Chembiochem : a European journal of chemical biology,    (13):   [PMID:19199284]
191. Oppermann, Felix S FS and 7 more authors..  (2009)  Large-scale proteomics analysis of the human kinome..  Molecular & cellular proteomics : MCP,      [PMID:19369195]
192. Maerki, Sarah S and 7 more authors..  (2009)  The Cul3-KLHL21 E3 ubiquitin ligase targets aurora B to midzone microtubules in anaphase and is required for cytokinesis..  The Journal of cell biology,    (14):   [PMID:19995937]
193. Nozawa, Ryu-Suke RS and 7 more authors..  (2010)  Human POGZ modulates dissociation of HP1alpha from mitotic chromosome arms through Aurora B activation..  Nature cell biology,      [PMID:20562864]
194. Mourón, Silvana S and 5 more authors..  (2010)  RINGO C is required to sustain the spindle-assembly checkpoint..  Journal of cell science,    (1):   [PMID:20605920]
195. Yamagishi, Yuya Y, Honda, Takashi T, Tanno, Yuji Y and Watanabe, Yoshinori Y..  (2010)  Two histone marks establish the inner centromere and chromosome bi-orientation..  Science (New York, N.Y.),    (8):   [PMID:20929775]
196. Wu, Liming L, Ma, Chi A CA, Zhao, Yongge Y and Jain, Ashish A..  (2011)  Aurora B interacts with NIR-p53, leading to p53 phosphorylation in its DNA-binding domain and subsequent functional suppression..  The Journal of biological chemistry,    (21):   [PMID:20959462]
197. Platica, Micsunica M and 5 more authors..  (2011)  PAR, a protein involved in the cell cycle, is functionally related to chromosomal passenger proteins..  International journal of oncology,      [PMID:21225229]
198. Wang, Fangwei F and 5 more authors..  (2011)  A positive feedback loop involving Haspin and Aurora B promotes CPC accumulation at centromeres in mitosis..  Current biology : CB,    (21):   [PMID:21658950]
199. Miduturu, Chandrasekhar V and 14 more authors..  (2011)  High-throughput kinase profiling: a more efficient approach toward the discovery of new kinase inhibitors..  Chemistry & biology,    (29):   [PMID:21802008]
200. Carlton, Jeremy G JG, Caballe, Anna A, Agromayor, Monica M, Kloc, Magdalena M and Martin-Serrano, Juan J..  (2012)  ESCRT-III governs the Aurora B-mediated abscission checkpoint through CHMP4C..  Science (New York, N.Y.),    (13):   [PMID:22422861]
201. Izumiyama, Tomohiro T, Minoshima, Shinsei S, Yoshida, Tetsuhiko T and Shimizu, Nobuyoshi N..  (2012)  A novel big protein TPRBK possessing 25 units of TPR motif is essential for the progress of mitosis and cytokinesis..  Gene,    (15):   [PMID:23036704]
202. Zhou, Houjiang H and 6 more authors..  (2013)  Toward a comprehensive characterization of a human cancer cell phosphoproteome..  Journal of proteome research,    (4):   [PMID:23186163]
203. Thoresen, Sigrid B SB and 7 more authors..  (2014)  ANCHR mediates Aurora-B-dependent abscission checkpoint control through retention of VPS4..  Nature cell biology,      [PMID:24814515]
204. Karthigeyan, Dhanasekaran D and 8 more authors..  (2016)  A Dual Non-ATP Analogue Inhibitor of Aurora Kinases A and B, Derived from Resorcinol with a Mixed Mode of Inhibition..  Chemical biology & drug design,      [PMID:26808391]
205. Mo, Fei F and 17 more authors..  (2016)  Acetylation of Aurora B by TIP60 ensures accurate chromosomal segregation..  Nature chemical biology,      [PMID:26829474]
206. Sasai, Kaori K, Katayama, Hiroshi H, Hawke, David H DH and Sen, Subrata S..  (2016)  Aurora-C Interactions with Survivin and INCENP Reveal Shared and Distinct Features Compared with Aurora-B Chromosome Passenger Protein Complex..  PloS one,      [PMID:27332895]
207. Thomas R Burkard,Melanie Planyavsky,Ines Kaupe,Florian P Breitwieser,Tilmann Bürckstümmer,Keiryn L Bennett,Giulio Superti-Furga,Jacques Colinge.  (2011-01-29)  Initial characterization of the human central proteome..  BMC systems biology,  5  (17-17).  [PMID:21269460]

Solution Calculators

Privacy Policy Website Terms of Use Return policy Terms and Conditions of Sale Cookie Policy Sales Policy
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Copyright © 2023-present Aladdin Scientific Corp . All rights reserved.